ClinicalTrials.gg
RecruitingNCT06100770ARRIVEUpdated Oct 19, 2026

Aveir AR Coverage With Evidence Development (CED) Study

An observational study in Cardiac Pacemaker, Arrhythmia and Bradycardia, sponsored by Abbott Medical Devices. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Primary conditionBradycardiaRegistry: Arrhythmias, CardiacReclassifiedWhy we changed it
Registry
Arrhythmias, Cardiac — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bradycardia
Why
  1. The study's listed conditions name Bradycardia, a narrower term within Arrhythmias, Cardiac.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Abbott Medical Devices (part of Abbott) · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
586
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Bradycardia by Abbott — 5 open to participants now, 8 under way, none of them phase 3. Bradycardia · Abbott.

Planned enrollment
9th of 17
586 · median 586
Started
2024
with 1 other
Observational
17 of 28
3 open now
Registered
24th of 28
by date

Among the 28 studies in Bradycardia by Abbott, this one is the 9th largest by planned enrollment of the 17 observational ones that give a count, is one of 2 that started in 2024, is one of 17 observational ones, and was the 24th registered.

Bradycardia

317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.

Browse Bradycardia studies →

Open to participants now

5 of the 28 studies in Bradycardia by Abbott are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 51 Bradycardia studies recruiting now, 34 (67%) set no upper age limit and 9 (18%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Bradycardia by Abbott, or all of them as a file.
02

Study summary

The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the single-chamber Aveir Atrial Leadless Pacemaker device (aka Aveir™ AR LP system).

Read the detailed description

This CED study utilizes a real-world evidence (RWE) method merging multiple real-world datasets from Abbott and the Center for Medicare Services to assess Aveir AR LP health outcomes among Medicare beneficiaries.

The study will enroll all Medicare patients with continuous claims data implanted with the Aveir AR LP or a single-chamber atrial transvenous pacemaker system from any manufacturer.

Due to the RWE data collection methods used in this study, a central institutional review board (IRB) approved informed consent waiver has been granted. Due to this waiver and the sponsor's use of the central IRB, individual hospitals are not required to consent patients or complete local IRB submissions for this RWE study.

03

Conditions studied

  • Cardiac Pacemaker
  • Arrhythmia
  • Bradycardia

Browse trials for

04

In context

Bradycardia Reclassified

317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.

This study's planned enrollment of 586 is above the median of 257 across 127 observational studies indexed under Bradycardia.

Browse Bradycardia studies →

Lead sponsor

Abbott Medical Devices is the lead sponsor of 541 studies on the registry; 34 are open to participants now.

Of its 53 completed or terminated interventional studies of FDA-regulated products, 44 (83%) have results posted.

Compared within Bradycardia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arrhythmias, Cardiac. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study cohort will include all Medicare patients with continuous claims data implanted with an Aveir DR leadless pacemaker or a full-system dual-chamber transvenous pacemaker (from any manufacturer) in any US location.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Medicare beneficiaries implanted with an Aveir AR leadless pacemaker on or after the study start date (i.e., the date of Aveir AR market approval) will be included in the study.

    OR

  2. Medicare beneficiaries implanted with a full system (e.g. lead and generator) single chamber atrial transvenous pacemaker on or after the study start date

Exclusion criteria

Exclusion Criteria:

  • None
06

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
586 participants (estimated)
Patient registry
No

Groups and cohorts

  • Aveir AR Leadless Pacemaker

    This study will utilize real-world data from patients implanted with the Aveir AR Leadless Pacemaker. No device intervention is required in this study.

    Device: Aveir AR Leadless Pacemaker

  • Single-Chamber Atrial Transvenous Pacemaker

    This study will utilize real-world data from patients implanted with a single-chamber atrial transvenous pacemaker as a comparator to the Aveir AR LP study arm. No device intervention is required in this study.

    Device: Single-chamber atrial transvenous pacemaker

Interventions

  • DeviceAveir AR Leadless Pacemaker

    This study will utilize real-world data from patients implanted with the Aveir AR Leadless Pacemaker. No device intervention is required in this study.

  • DeviceSingle-chamber atrial transvenous pacemaker

    This study will utilize real-world data from patients implanted with a single-chamber atrial transvenous pacemaker as a comparator to the Aveir AR LP study arm. No device intervention is required in this study

07

What researchers measure

Primary outcomes

  1. Acute device-related complication rate

    Assess the acute (30-day) complication rate of the Aveir AR LP, compared to single chamber atrial transvenous pacemakers. An acute complication is defined as a peri-procedural, device-related adverse event occurring within 30 days post-implant.

    Time frame: 30 days

  2. Two-year survival rate

    Assess (2-year) survival rate of subjects implanted with an Aveir AR LP, compared to single chamber atrial transvenous pacemakers.

    Time frame: 2 years

Secondary outcomes

  1. Chronic complication rate

    • To assess the chronic (6-month) complication rate of the Aveir AR LP, compared to single chamber atrial transvenous pacemakers. A chronic complication is defined as a post-procedural, device-related adverse event that requires invasive intervention to resolve, occurring more than 30 days through six months post implant.

    Time frame: 6 months

  2. Device related re-intervention rate

    • To assess (2-year) device-related re-intervention rates of the Aveir AR LP, compared to single chamber atrial transvenous pacemakers.

    Time frame: 2 years

08

Study locations

1 of 1 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2030, 72 months after the start.

Of 35 industry-sponsored observational studies under Bradycardia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 79. This study's planned 72 months is above that.

Counting every sponsor, half of 73 studies reached it within 42 months; a quarter within 18 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Oct 25, 2023
StartActual
Jan 18, 2024
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2031
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms and verification date
1 update, last Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Minor edits only
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06100770
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Jan 18, 2024
Primary completion
Jan 2030 (estimated)
Completion
Jan 2031 (estimated)
Last update
Oct 19, 2026

Study contacts

Nicole Harbert
Contact
nicole.harbert@abbott.com
972-526-4841
Stephanie Delgado
Contact
stephanie.delgado1@abbott.com
818-493-3285
Nicole Harbert
study director · Abbott

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion